Retirement Wealth Solutions LLC Invests $73,000 in Johnson & Johnson (NYSE:JNJ)

Retirement Wealth Solutions LLC bought a new position in Johnson & Johnson (NYSE:JNJ) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 512 shares of the company’s stock, valued at approximately $73,000.

A number of other large investors have also modified their holdings of JNJ. Pacer Advisors Inc. grew its stake in Johnson & Johnson by 15.3% during the 2nd quarter. Pacer Advisors Inc. now owns 240,605 shares of the company’s stock valued at $35,167,000 after purchasing an additional 31,908 shares in the last quarter. Kowal Investment Group LLC grew its position in shares of Johnson & Johnson by 1.2% during the second quarter. Kowal Investment Group LLC now owns 9,888 shares of the company’s stock worth $1,445,000 after buying an additional 121 shares in the last quarter. ProShare Advisors LLC increased its stake in shares of Johnson & Johnson by 9.8% in the second quarter. ProShare Advisors LLC now owns 1,651,733 shares of the company’s stock worth $241,417,000 after buying an additional 147,609 shares during the last quarter. Prospector Partners LLC raised its holdings in Johnson & Johnson by 1.0% in the second quarter. Prospector Partners LLC now owns 66,134 shares of the company’s stock valued at $9,666,000 after acquiring an additional 660 shares in the last quarter. Finally, Frank Rimerman Advisors LLC grew its holdings in Johnson & Johnson by 1,811.6% during the 2nd quarter. Frank Rimerman Advisors LLC now owns 31,541 shares of the company’s stock worth $4,610,000 after acquiring an additional 29,891 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Activity

In related news, Director Mark A. Weinberger bought 1,000 shares of the stock in a transaction on Thursday, December 12th. The shares were purchased at an average price of $147.22 per share, with a total value of $147,220.00. Following the purchase, the director now owns 1,000 shares in the company, valued at approximately $147,220. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Performance

JNJ opened at $147.03 on Monday. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $168.85. The stock has a market cap of $353.99 billion, a PE ratio of 21.28, a price-to-earnings-growth ratio of 2.30 and a beta of 0.51. The business’s 50 day moving average is $148.51 and its 200-day moving average is $156.03. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.37%. Johnson & Johnson’s payout ratio is 71.78%.

Analyst Ratings Changes

Several brokerages have recently commented on JNJ. Morgan Stanley increased their price target on shares of Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 16th. Wolfe Research initiated coverage on Johnson & Johnson in a research report on Friday, November 15th. They issued an “outperform” rating and a $190.00 target price for the company. Citigroup dropped their price target on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research report on Wednesday, December 11th. Royal Bank of Canada lifted their price objective on shares of Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a report on Wednesday, October 16th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a report on Wednesday, October 16th. Seven analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $174.29.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.